CN114805269A - 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用 - Google Patents

毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用 Download PDF

Info

Publication number
CN114805269A
CN114805269A CN202210370822.3A CN202210370822A CN114805269A CN 114805269 A CN114805269 A CN 114805269A CN 202210370822 A CN202210370822 A CN 202210370822A CN 114805269 A CN114805269 A CN 114805269A
Authority
CN
China
Prior art keywords
eriocalyxin
derivative
preparation
acetone
hresims
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210370822.3A
Other languages
English (en)
Other versions
CN114805269B (zh
Inventor
普诺·白玛丹增
孙汉董
周元飞
颜秉超
杨谦
杜雪
胡坤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kunming Institute of Botany of CAS
Original Assignee
Kunming Institute of Botany of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kunming Institute of Botany of CAS filed Critical Kunming Institute of Botany of CAS
Priority to CN202210370822.3A priority Critical patent/CN114805269B/zh
Publication of CN114805269A publication Critical patent/CN114805269A/zh
Application granted granted Critical
Publication of CN114805269B publication Critical patent/CN114805269B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明公开了毛萼内酯素B衍生物与其在制药中的应用。属于药物技术领域。本发明提供了毛萼内酯素B及其衍生物新的药用用途，可用于制备抗肿瘤药物。本发明化合物对人宫颈癌细胞株（Hela），卵巢癌细胞株（SK‑OV‑3），肝癌细胞株（SK‑HEP‑1），结肠癌株（CACO2），乳腺癌细胞株（MDA‑MB‑231），前列腺癌细胞株（PC‑3），结肠癌细胞株（SW480），人肺癌紫杉醇耐药株（A549/Taxol）等细胞均有较显著的抑制作用。提供毛萼内酯素B及其衍生物在细胞水平上抑制多种肿瘤细胞的生长，具有强细胞毒作用。

Description

毛萼内酯素B衍生物与其在制备抗肿瘤药物中的应用
技术领域
本发明属于药物技术领域，具体地，本发明涉及毛萼内酯素B衍生物与其药物组合物，它们的制备方法，及其在制药中的应用。
背景技术
肿瘤是人类健康的重要威胁，对映-贝壳杉烷型二萜被报道具有广泛的抗肿瘤活性。其中基于A环环系的改造及14位羟基的修饰是目前提升抗肿瘤活性的关键。国内外研究者将该类化合物A环、D环及C-14位羟基进行酯化衍生化(见ZL201611034438.7；ZL200710133915.X；ZL201010509348.5；ZL201110178862.X；ZL201310423035.1)。毛萼内酯素B衍生物的A环具有特殊的重排结构，该类型化合物在抗肿瘤用途方面尚未报道。
发明内容
本发明目的是提供毛萼内酯素B及其衍生物及其药物组合物与其制备方法，它们在制备抗肿瘤药物中的应用。本发明通过创造性的研究发现毛萼内酯素B及其衍生物对对宫颈癌细胞(Hela)，结肠癌细胞(CACO2)，人卵巢癌细胞(SK-OV-3)，人肝癌细胞(SK-HEP-1，高转移)，人结肠癌细胞(SW480)，人肺癌紫杉醇耐药株细胞(A549/Taxol)，前列腺癌细胞(PC-3)，乳腺癌细胞(MDA-MB-231)，L02(人正常肝细胞)具有潜在的治疗效果。
为了实现本发明的上述目的，本发明提供了如下的技术方案：
如下结构式所示的毛萼内酯素B及其衍生物
Figure BDA0003586979280000011
其中R为以下官能团：
Figure BDA0003586979280000021
本发明同时提供了毛萼内酯素B衍生物的制备方法，该方法以毛萼内酯素B为起始原料，通过酯化反应得到毛萼内酯素B衍生物，
Figure BDA0003586979280000022
该方法包括如下步骤：氩气保护下，将毛萼内酯素B溶解在0.1～0.5mL的二氯甲烷中，加入EDCI及DMAP，将反应置于室温中反应1～12个小时，TLC检测反应完全后，饱和NaHCO3淬灭，EtOAc萃取，饱和食盐水洗涤、无水MgSO4干燥，过滤，浓缩后柱层析纯化或经过制备纯化，分离得到毛萼内酯素B衍生物。
本发明同时提供了毛萼内酯素B衍生物在制备抗肿瘤药物中的应用。
以及，毛萼内酯素B衍生物在制备宫颈癌、结肠癌、卵巢癌、肺癌、前列腺癌、乳腺癌、肝癌的药物中的应用。
本发明另外还提供了一种药物组合物，含有毛萼内酯素B或其衍生物任其一或任其组合及可药用载体。
所述的药物组合物的剂型为粉剂、颗粒剂、片剂、胶囊剂、丸剂、溶液、悬浮液或注射液。
此外，本发明还提供了所述的药物组合物的制备方法，先按上述制备毛萼内酯素B衍生物的方法，分离得到毛萼内酯素B衍生物，然后再加入可药用载体。
同时，本发明提供了所述的药物组合物在制备抗肿瘤药物中的应用。
以及，所述的药物组合物在制备宫颈癌、结肠癌、卵巢癌、肺癌、前列腺癌、乳腺癌、肝癌的药物中的应用。
本发明化合物用作药物时，可以直接使用，或者以药物组合物的形式使用。该药物组合物含有0.1-99％，优选0.5-90％的本发明化合物，其余为药物学上可接受的，对人和动物无毒和惰性的可药用载体和/或赋形剂。
所述的药用载体或赋形剂是一种或多种固体、半固体和液体稀释剂、填料以及药物制品辅剂。将本发明的药物组合物以单位体重服用量的形式使用。本发明的药物可经多种形式(液体制剂、固体制剂、注射剂、外用制剂、喷剂、复方制剂)给药。
与现有技术相比，本发明具备如下的优益性：
1.本发明提供了一类新的毛萼内酯素B衍生物，填补了现有技术的空白。
2.本发明提供了制备毛萼内酯素B衍生物的方法，该方法原料易得，易于操作，收率高，适于工业化生产。
3.本发明提供了毛萼内酯素B衍生物作为有效成分的药物组合物，为新的抗肿瘤药物提供了具有较好药用作用的新的药物。
4.本发明的毛萼内酯素B衍生物对人宫颈癌细胞株(Hela)，卵巢癌细胞株(SK-OV-3)，肝癌细胞株(SK-HEP-1)，结肠癌株(CACO2)，乳腺癌细胞株(MDA-MB-231)，前列腺癌细胞株(PC-3)，结肠癌细胞株(SW480)，人肺癌紫杉醇耐药株(A549/Taxol)都有较好的抑制效果。
5.毛萼内酯素B衍生物可作为药物用于治疗相关的疾病。可用于制备抗肿瘤药物，用于制备宫颈癌、结肠癌、卵巢癌、肺癌、前列腺癌、乳腺癌、肝癌的药物。
附图说明
图1毛萼内酯素B及其衍生物的IC50示意图；
图2毛萼内酯素B衍生物结构示意图。
具体实施方式
下面结合附图，用本发明的实施例来对本发明作进一步的说明，但不以任何方式对本发明加以限制，基于本发明教导所作的任何变换或改进，均落入本发明的保护范围
实施例1
1.先制备毛萼内酯素B：
制备中间体L：将化合物K溶解在(1～100mL)的丙酮中，在0℃冰浴条件下添加琼斯试剂(10mL)反应15分钟，使用TLC检测反应完全后，使用异丙醇淬灭，加水稀释后EtOAc萃取，饱和食盐水洗涤，无水MgSO4干燥，过滤，浓缩后柱层析纯化，得到无定型固体化合物L，经质谱、一维和二维核磁共振鉴定化合物为中间体L。
Figure BDA0003586979280000041
制备中间体M：将化合物L溶解在(1～100mL)的1，2-二氯乙烷中，在0℃冰浴条件下加入NaBH(OAc)3(1～50g)后随后缓慢滴加乙酸(0.1～1mL)反应10分钟，使用TLC检测反应完全后，使用丙酮淬灭，加水稀释后EtOAc萃取，饱和食盐水洗涤，无水MgSO4干燥，过滤，浓缩后柱层析纯化，得到无定型固体化合物，经质谱、一维和二维核磁共振鉴定化合物为中间体M。
Figure BDA0003586979280000042
制备中间体N：将化合物M溶解在(1～100mL)的二氯甲烷中，在0℃冰浴条件下依次添加DIPEA(1～50mL)以及TMSCl(1～50mL)，在冰浴条件下反应30分钟后减压浓缩。浓缩后产品溶解于乙腈，后依次添加DBU(1～50mL)和对甲苯磺酰叠氮(1～50mL)反应2小时后滴加TBAF(1～50g)反应30分钟，使用TLC检测反应完全后，加水稀释加EtOAc萃取，饱和食盐水洗涤，无水MgSO4干燥，过滤，浓缩后柱层析纯化，得到无定型固体化合物，经质谱、一维和二维核磁共振鉴定化合物为中间体N。
Figure BDA0003586979280000051
制备中间体O：将化合物N溶解在(1～100mL)的二氯甲烷中，在0℃冰浴条件下依次添加NaHCO3(1～10g)以及戴斯-马丁试剂(1～10g)，在冰浴条件下反应10分钟，使用TLC检测反应完全后，使用Na2O3S2淬灭，加水稀释加EtOAc萃取，饱和食盐水、洗涤，无水MgSO4干燥，过滤，浓缩后柱层析纯化，得到无定型固体化合物，经质谱、一维和二维核磁共振鉴定化合物为中间体O。
Figure BDA0003586979280000052
制备毛萼内酯素B：将化合物O溶解于(1～50mL)甲苯中，放置于110℃加热搅拌下充分反应两个小时。TLC检测反应完全后，将反应挪到室温，待冷却后，直接减压浓缩，浓缩后柱层析纯化，得到无定型白色固体化合物，经质谱、一维和二维核磁共振鉴定化合物为毛萼内酯素B。
Figure BDA0003586979280000053
2.制备毛萼内酯素B衍生物：
氩气保护下，将毛萼内酯素B(10～20mg)溶解在(0.1～0.5mL)的二氯甲烷中，加入EDCI(10～50mg)及DMAP(10～50mg)，将反应置于室温中反应1～12个小时，TLC检测反应完全后，饱和NaHCO3淬灭，EtOAc萃取，饱和食盐水洗涤、无水MgSO4干燥，过滤，浓缩后柱层析纯化或经过制备纯化，得到化合物经质谱、一维共振鉴定的衍生物1-63。
Figure BDA0003586979280000054
Figure BDA0003586979280000061
实施例2
毛萼内酯素B衍生物核磁、质谱数据：
Figure BDA0003586979280000062
Data for 1:1H NMR(600MHz,Acetone-d6)δ＝6.09(s,1H),5.67(s,1H),5.59(s,1H),4.93(d,J＝10.8,1H),4.87(d,J＝10.8,1H),4.52(dt,J＝14.3,3.6,1H),4.06(d,J＝3.7,1H),2.88(dd,J＝11.7,3.3,1H),2.49(dd,J＝9.2,2.6,1H),2.48–2.41(m,1H),2.23(dd,J＝13.8,11.8,1H),2.20–2.15(m,1H),2.11(t,J＝7.4,1H),1.99–1.92(m,2H),1.90(dd,J＝13.9,3.3,1H),1.82–1.73(m,1H),1.68–1.62(m,1H),1.49(q,J＝7.4,2H),1.24(s,3H),1.21(s,3H),0.86(t,J＝7.4,3H)；HRESIMS(m/z):[M+Na]+calcd for C24H30O7Na+430.1884,found 430.1892.
Data for 2:1H NMR(600MHz,Acetone-d6)δ＝6.09(s,1H),5.68(d,J＝1.4,1H),5.59(d,J＝1.3,1H),5.49(s,1H),4.96(d,J＝10.8,1H),4.91(d,J＝10.8,1H),4.58(dt,J＝14.2,3.7,1H),4.02(d,J＝3.6,1H),3.33(s,1H),2.88(dd,J＝11.7,3.3,1H),2.48(dd,J＝9.3,2.3,1H),2.47–2.41(m,1H),2.24(dd,J＝13.9,11.7,1H),2.05(s,3H),1.99–1.95(m,1H),1.92(s,1H),1.90(dd,J＝13.8,3.4,1H),1.87(s,3H),1.78(s,1H),1.66(s,1H),1.25(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C25H30O7Na+465.1884,found465.1889.
Figure BDA0003586979280000071
Data for 3:1H NMR(600MHz,Acetone-d6)δ＝6.09(s,1H),5.67(d,J＝1.4,1H),5.59(s,1H),4.93(d,J＝10.8,1H),4.87(d,J＝10.8,1H),4.52(dt,J＝14.3,3.7,1H),4.04(d,J＝3.7,1H),2.88(dd,J＝11.7,3.3,1H),2.49(dd,J＝9.1,2.6,1H),2.47–2.40(m,1H),2.27–2.09(m,3H),1.99–1.93(m,2H),1.90(dd,J＝13.9,3.3,1H),1.82–1.73(m,1H),1.69–1.61(m,1H),1.51–1.44(m,2H),1.32–1.25(m,8H),1.24(s,3H),1.21(s,3H),0.87(t,J＝7.0,3H)；HRESIMS(m/z):[M+Na]+calcd for C28H38O7Na+509.2510,found 509.2516.
Data for 4:1H NMR(600MHz,Acetone-d6)δ＝6.09(s,1H),5.67(s,1H),5.60(s,1H),4.93(d,J＝10.8,1H),4.87(d,J＝10.8,1H),4.52(dt,J＝14.3,3.5,1H),4.06(d,J＝3.6,1H),3.33(s,1H),2.89(dd,J＝11.5,3.1,1H),2.49(dd,J＝9.2,2.5,1H),2.45–2.39(m,1H),2.26–2.08(m,3H),1.98–1.93(m,2H),1.90(dd,J＝13.9,3.2,1H),1.82–1.73(m,1H),1.68–1.60(m,1H),1.51–1.43(m,2H),1.33–1.24(m,10H),1.24(s,3H),1.21(s,3H),0.90–0.85(m,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H40O7Na+523.2666,found523.2658.
Figure BDA0003586979280000072
Data for 5:1H NMR(600MHz,Acetone-d6)δ＝6.10(s,1H),5.63(d,J＝1.4,1H),5.61(t,J＝1.0,1H),4.91(d,J＝10.9,1H),4.86(d,J＝10.8,1H),4.52(dd,J＝14.3,3.6,1H),4.11(d,J＝3.5,1H),3.35(s,1H),2.89–2.88(m,1H),2.48(dd,J＝9.3,2.4,1H),2.46–2.39(m,1H),2.23(dd,J＝13.9,11.8,1H),1.99–1.95(m,1H),1.93(d,J＝14.2,1H),1.89(dd,J＝13.8,3.3,1H),1.82–1.72(m,1H),1.67–1.60(m,1H),1.51–1.43(m,1H),1.23(s,3H),1.20(s,3H),0.86–0.79(m,3H),0.76(dt,J＝8.8,4.5,1H)；HRESIMS(m/z):[M+K]+calcd for C24H28O7K+467.1467,found 467.1463.
Data for 6:1H NMR(600MHz,Acetone-d6)δ＝6.08(s,1H),5.64(d,J＝1.4,1H),5.59(s,1H),4.94(d,J＝10.8,1H),4.88(d,J＝10.8,1H),4.56(dd,J＝14.3,3.7,1H),4.13(dd,J＝3.6,1.0,1H),3.32(s,1H),3.02–2.96(m,1H),2.89–2.88(m,1H),2.49(dd,J＝9.2,2.5,1H),2.47–2.40(m,1H),2.23(dd,J＝13.8,11.7,1H),2.13–2.09(m,4H),1.98–1.93(m,2H),1.92–1.87(m,2H),1.84–1.73(m,2H),1.68–1.61(m,1H),1.24(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C25H30O7Na+465.1884,found 465.1882.
Figure BDA0003586979280000081
Data for 7:1H NMR(600MHz,Acetone-d6)δ＝6.11–6.08(m,1H),5.63(d,J＝1.4,1H),5.59(t,J＝1.0,1H),4.93(d,J＝10.8,1H),4.88(d,J＝10.8,1H),4.54(dd,J＝14.3,3.7,1H),4.06(d,J＝3.7,1H),3.36–3.30(m,1H),2.88(dd,J＝11.7,3.3,1H),2.60–2.56(m,1H),2.49(dd,J＝9.2,2.5,1H),2.47–2.39(m,1H),2.23(dd,J＝13.9,11.7,1H),2.00–1.92(m,2H),1.90(dd,J＝13.9,3.3,1H),1.83–1.70(m,3H),1.70–1.62(m,3H),1.62–1.55(m,2H),1.55–1.47(m,2H),1.24(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd forC26H32O7Na+479.2040,found479.2042.
Data for 8:HRESIMS(m/z):1H NMR(600MHz,Acetone-d6)δ＝6.62(q,J＝2.3,1H),6.10(s,1H),5.67(d,J＝1.4,1H),5.60(s,1H),4.97(d,J＝10.8,1H),4.90(d,J＝10.8,1H),4.58(dd,J＝14.2,3.7,1H),4.06(d,J＝3.7,1H),3.38(d,J＝3.9,1H),2.89(dd,J＝11.7,3.4,1H),2.50(dd,J＝9.1,2.4,1H),2.48–2.36(m,5H),2.24(dd,J＝13.9,11.7,1H),2.00–1.93(m,2H),1.93–1.86(m,3H),1.83–1.74(m,1H),1.66(s,1H),1.25(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C26H30O7Na+477.1884,found 477.1888.
Figure BDA0003586979280000082
Data for 9:1HNMR(600MHz,Acetone-d6)δ＝6.10(s,1H),5.67(d,J＝1.4,1H),5.61(s,1H),4.93(d,J＝10.8,1H),4.86(d,J＝10.8,1H),4.55(dd,J＝14.3,3.7,1H),4.25(dd,J＝8.7,4.1,1H),4.17(d,J＝3.6,1H),3.82–3.75(m,2H),3.38–3.32(m,1H),2.89(dd,J＝11.7,3.4,1H),2.51(dd,J＝9.1,2.7,1H),2.48–2.40(m,1H),2.24(dd,J＝13.9,11.7,1H),2.13–2.09(m,1H),1.99–1.93(m,2H),1.93–1.84(m,3H),1.84–1.74(m,2H),1.69–1.63(m,1H),1.24(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C25H30O8Na+481.1833,found 481.1842.
Data for 10:1H NMR(600MHz,Acetone-d6)δ＝7.81(d,J＝1.8,1H),7.10(d,J＝3.5,1H),6.65–6.59(m,1H),6.14(s,1H),5.85(s,1H),5.65(s,1H),4.98(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.62(dd,J＝14.2,3.4,1H),4.14(d,J＝3.6,1H),3.49(d,J＝3.9,1H),2.91(dd,J＝11.7,3.3,1H),2.55(dd,J＝9.1,2.7,1H),2.53–2.46(m,1H),2.25(dd,J＝13.9,11.7,1H),2.02–1.96(m,2H),1.92(dd,J＝13.9,3.3,1H),1.86–1.77(m,1H),1.73–1.67(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C25H26O8Na+477.1520,found 477.1524.
Figure BDA0003586979280000091
Data for 11:1H NMR(600MHz,Acetone-d6)δ＝7.86(dd,J＝5.0,1.3,1H),7.66(dd,J＝3.8,1.3,1H),7.18(dd,J＝5.0,3.7,1H),6.15(s,1H),5.85(d,J＝1.4,1H),5.66(s,1H),5.00(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.64(dd,J＝14.2,3.5,1H),4.13(s,1H),3.51(s,1H),2.91(dd,J＝11.7,3.4,1H),2.56(dd,J＝9.1,2.7,1H),2.54–2.46(m,1H),2.25(dd,J＝13.9,11.7,1H),2.03–1.97(m,2H),1.92(dd,J＝13.9,3.4,1H),1.87–1.77(m,1H),1.73–1.67(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcdfor C25H26O7SNa+493.1291,found 493.1289.
Data for 12:1H NMR(600MHz,Acetone-d6)δ＝7.05(s,1H),6.71(s,1H),6.18(s,1H),6.12(s,1H),5.79(d,J＝1.4,1H),5.61(d,J＝1.0,1H),4.99(d,J＝10.8,1H),4.95(d,J＝10.8,1H),4.64(dd,J＝14.2,3.6,1H),4.07(d,J＝3.6,1.1,1H),3.44(d,J＝3.9,1H),2.90(dd,J＝11.7,3.3,1H),2.52(dd,J＝9.3,2.4,1H),2.50–2.44(m,1H),2.25(dd,J＝13.9,11.7,1H),2.02–1.93(m,2H),1.91(dd,J＝13.9,3.4,1H),1.85–1.77(m,1H),1.70–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C25H27NO7Na+476.1680,found 476.1677.
Figure BDA0003586979280000092
Data for 13:1H NMR(600MHz,Acetone-d6)δ＝8.40(d,J＝2.1,1H),7.72(d,J＝2.0,1H),6.16(s,1H),5.92(s,1H),5.67(s,1H),4.97(d,J＝10.8,1H),4.90(d,J＝10.8,1H),4.60(dd,J＝14.2,3.7,1H),4.19(d,J＝3.6,1H),3.52(s,1H),2.92(dd,J＝11.7,3.3,1H),2.58(dd,J＝9.2,3.0,1H),2.56–2.48(m,1H),2.25(dd,J＝13.9,11.7,1H),2.00(dd,J＝12.4,8.1,2H),1.93–1.90(m,1H),1.86–1.78(m,1H),1.75–1.68(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C24H25NO8Na+456.1653,found 456.1654.
Data for 14:1H NMR(600MHz,Acetone-d6)δ＝9.25(s,1H),8.34(s,1H),6.16(s,1H),5.90(s,1H),5.67(s,1H),4.98(d,J＝10.8,1H),4.91(d,J＝10.9,1H),4.62(dd,J＝14.2,3.6,1H),4.20(d,J＝3.7,1H),3.54(d,J＝3.9,1H),2.92(dd,J＝11.7,3.4,1H),2.58(dd,J＝9.0,2.9,1H),2.55–2.48(m,1H),2.26(dd,J＝13.8,11.8,1H),2.03–1.99(m,2H),1.92(dd,J＝13.8,3.3,1H),1.86–1.78(m,1H),1.71(ddt,J＝15.7,6.6,3.0,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C24H25NO7SNa+472.1424,found472.1428.
Figure BDA0003586979280000101
Data for 15:1H NMR(600MHz,Acetone-d6)δ＝9.50(s,1H),6.16(s,1H),6.02(d,J＝1.4,1H),5.68(d,J＝1.2,1H),5.00(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.65(dd,J＝14.2,3.5,1H),4.22(d,J＝3.6,1H),3.60–3.58(m,1H),2.93(dd,J＝11.7,3.4,1H),2.62–2.60(m,1H),2.59–2.52(m,1H),2.26(dd,J＝13.8,11.7,1H),2.04–2.01(m,2H),1.93(dd,J＝13.9,3.4,1H),1.88–1.81(m,1H),1.77–1.71(m,1H),1.26(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C23H24N2O7SNa+495.1196,found 495.1198.
Data for 16:1H NMR(600MHz,Acetone-d6)δ＝6.09(s,1H),5.63(s,1H),5.59(s,1H),4.93(d,J＝10.8,1H),4.88(d,J＝10.8,1H),4.53(dd,J＝14.3,3.4,1H),4.08(d,J＝3.6,1H),3.32(d,J＝4.1,1H),2.88(dd,J＝11.7,3.3,1H),2.80(s,1H),2.48(dd,J＝9.2,2.4,1H),2.47–2.40(m,1H),2.23(dd,J＝13.9,11.7,1H),2.16–2.10(m,1H),1.99–1.92(m,2H),1.90(dd,J＝13.9,3.3,1H),1.82–1.72(m,3H),1.65(s,3H),1.61–1.55(m,1H),1.31–1.24(m,3H),1.24(s,3H),1.21(s,3H),1.20–1.13(m,1H)；HRESIMS(m/z):[M–H]–calcd forC27H33O7 –469.2232,found 469.2233.
Figure BDA0003586979280000102
Data for 17:1H NMR(600MHz,Acetone-d6)δ＝6.82–6.77(m,1H),6.10(s,1H),5.67(d,J＝1.4,1H),5.60(s,1H),4.97(d,J＝10.8,1H),4.90(d,J＝10.8,1H),4.58(dd,J＝14.3,3.7,1H),4.06(d,J＝3.7,1H),3.38(d,J＝4.1,1H),2.88(dd,J＝11.7,3.4,1H),2.50(dd,J＝9.2,2.3,1H),2.47–2.41(m,1H),2.24(dd,J＝13.9,11.7,1H),2.17–2.12(m,2H),2.08–2.06(m,2H),2.00–1.93(m,2H),1.90(dd,J＝13.9,3.4,1H),1.83–1.74(m,1H),1.69–1.62(m,1H),1.61–1.51(m,4H),1.25(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C27H32O7Na+491.2040,found 491.2041.
Data for 18:1H NMR(600MHz,Acetone-d6)δ＝7.86–7.82(m,2H),7.66–7.62(m,1H),7.51–7.47(m,2H),6.16(s,1H),5.90(d,J＝1.5,1H),5.66(s,1H),5.02(d,J＝10.8,1H),4.96(d,J＝10.8,1H),4.65(dt,J＝14.3,3.7,1H),4.14(d,J＝3.5,1H),3.53(s,1H),2.92(dd,J＝11.7,3.4,1H),2.57(dd,J＝9.1,2.5,1H),2.55–2.48(m,1H),2.26(dd,J＝13.8,11.8,1H),2.00(d,J＝14.3,2H),1.92(dd,J＝13.9,3.3,1H),1.88–1.79(m,1H),1.74–1.68(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C27H28O7Na+478.1727,found 478.1726.
Figure BDA0003586979280000111
Data for 19:1H NMR(800MHz,Acetone-d6)δ＝88.80–8.76(m,2H),7.69–7.65(m,2H),6.18(s,1H),5.95(d,J＝1.4,1H),5.68(d,J＝1.0,1H),5.00(d,J＝10.7,1H),4.94(d,J＝10.7,1H),4.63(dd,J＝14.2,3.6,1H),4.21(d,J＝3.6,1H),3.57(dt,J＝4.8,2.3,1H),2.93(dd,J＝11.7,3.4,1H),2.60(dd,J＝9.3,3.0,1H),2.56–2.50(m,1H),2.26(dd,J＝13.9,11.8,1H),2.04–2.02(m,2H),1.93(dd,J＝13.9,3.4,1H),1.85–1.84(m,1H),1.74–1.72(m,1H),1.26(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+H]+calcd for C26H28NO7+466.1860,found 466.1863.
Data for 20:1H NMR(800MHz,Acetone-d6)δ＝9.01(d,J＝1.5,1H),8.84(d,J＝2.4,1H),8.75(dd,J＝2.3,1.5,1H),6.18(s,1H),6.00(d,J＝1.4,1H),5.69(s,1H),5.00(d,J＝10.7,1H),4.95(d,J＝10.8,1H),4.64(dd,J＝14.2,3.6,1H),4.24(d,J＝3.5,1H),3.58(d,J＝3.1,1H),2.93(dd,J＝11.8,3.4,1H),2.61(d,J＝7.7,1H),2.57–2.52(m,1H),2.27(dd,J＝13.9,11.8,1H),2.04–2.02(m,2H),1.93(dd,J＝13.9,3.4,1H),1.87–1.82(m,1H),1.76–1.72(m,1H),1.26(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+H]+calcd forC25H27N2O7 +467.1813,found 467.1815.
Figure BDA0003586979280000112
Data for 21:1H NMR(800MHz,Acetone-d6)δ＝9.35(s,1H),9.06(s,2H),6.19–6.17(m,1H),5.98(d,J＝1.4,1H),5.68(d,J＝1.0,1H),4.99(d,J＝10.7,1H),4.93(d,J＝10.7,1H),4.64–4.61(m,1H),4.27(s,1H),3.60(s,1H),2.93(dd,J＝11.8,3.4,1H),2.61(d,J＝5.8,1H),2.56–2.51(m,1H),2.26(dd,J＝13.9,11.7,1H),2.04–2.01(m,2H),1.92(dd,J＝13.9,3.4,1H),1.87–1.81(m,1H),1.75–1.71(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+H]+calcd for C25H27N2O7 +467.1813,found 467.1817.
Data for 22:1H NMR(600MHz,Acetone-d6)δ＝7.96–7.84(m,2H),7.34–7.18(m,2H),6.16(s,1H),5.88(s,1H),5.66(s,1H),5.01(d,J＝10.8,1H),4.95(d,J＝10.7,1H),4.68–4.58(m,1H),4.17(d,J＝3.7,1H),3.53(s,1H),2.98(s,1H),2.57(dd,J＝9.2,2.6,1H),2.54–2.46(m,1H),2.25(dd,J＝13.9,11.8,1H),2.00(d,J＝14.3,2H),1.91(dd,J＝13.8,3.3,1H),1.88–1.76(m,1H),1.75–1.66(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C27H27FO7Na+505.1633,found 505.1632.
Figure BDA0003586979280000121
Data for 23:1H NMR(600MHz,Acetone-d6)δ＝7.85–7.80(m,2H),7.57–7.52(m,2H),6.16(s,1H),5.90(d,J＝1.4,1H),5.66(s,1H),5.01(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.64(d,J＝14.2,1H),4.19(s,1H),3.53(s,1H),2.94–2.92(m,1H),2.57(dd,J＝9.1,2.6,1H),2.54–2.48(m,1H),2.25(dd,J＝13.9,11.7,1H),2.03–1.98(m,2H),1.91(dd,J＝13.9,3.3,1H),1.87–1.79(m,1H),1.74–1.68(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C27H26ClO7 –497.1373,found 497.1372.
Data for 24:1H NMR(600MHz,Acetone-d6)δ＝7.78–7.73(m,2H),7.73–7.68(m,2H),6.16(s,1H),5.90(s,1H),5.66(s,1H),5.00(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.63(dd,J＝14.2,3.6,1H),4.16(d,J＝3.6,1H),3.53(s,1H),2.92(dd,J＝11.8,3.3,1H),2.57(dd,J＝9.1,2.6,1H),2.55–2.48(m,1H),2.25(dd,J＝13.9,11.8,1H),2.03–1.98(m,2H),1.92(dd,J＝13.9,3.3,1H),1.87–1.79(m,1H),1.74–1.68(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C27H27BrO7Na+565.0832,found 565.0826.
Figure BDA0003586979280000122
Data for 25:1H NMR(600MHz,Acetone-d6)δ＝8.02(d,J＝8.1,2H),7.86(d,J＝8.1,2H),6.16(s,1H),5.94(s,1H),5.67(s,1H),5.00(d,J＝10.7,1H),4.94(d,J＝10.8,1H),4.63(dt,J＝14.3,3.5,1H),4.19(d,J＝3.5,1H),3.56(d,J＝3.8,1H),2.92(dd,J＝11.8,3.3,1H),2.58(d,J＝8.6,1H),2.55–2.50(m,1H),2.25(dd,J＝13.8,11.8,1H),2.03–1.99(m,2H),1.91(dd,J＝14.0,3.3,1H),1.86–1.80(m,1H),1.74–1.69(m,1H),1.25(s,3H),1.21(s,3H)；HRESIMS(m/z):[M–H]–calcd for C27H26NO9 –508.1613,found 508.1613.
Data for 26:1H NMR(600MHz,Acetone-d6)δ＝7.80–7.77(m,2H),7.02–6.98(m,2H),6.15(s,1H),5.84(d,J＝1.4,1H),5.65(s,1H),5.02(d,J＝10.8,1H),4.96(d,J＝10.8,1H),4.65(dd,J＝14.2,3.3,1H),4.12(d,J＝3.5,1H),3.87(s,3H),3.50(d,J＝3.9,1H),2.91(dd,J＝11.7,3.3,1H),2.55(dd,J＝9.2,2.3,1H),2.53–2.47(m,1H),2.25(dd,J＝13.9,11.8,1H),2.03–1.96(m,2H),1.91(dd,J＝13.9,3.3,1H),1.86–1.78(m,1H),1.72–1.67(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C28H29O8 –493.1868,found 493.1865.
Figure BDA0003586979280000131
Data for 27:1H NMR(600MHz,Acetone-d6)δ＝7.72(d,J＝7.9,2H),7.30(d,J＝7.9,2H),6.16(s,1H),5.87(s,1H),5.65(d,J＝1.3,1H),5.02(d,J＝10.8,1H),4.96(d,J＝10.8,1H),4.65(dd,J＝14.3,3.3,1H),4.14(d,J＝3.5,1H),3.51(d,J＝3.8,1H),2.92(dd,J＝11.8,3.2,1H),2.56(dd,J＝9.1,2.3,1H),2.54–2.48(m,1H),2.39(s,3H),2.25(dd,J＝13.8,11.8,1H),2.03–1.97(m,2H),1.92(dd,J＝13.9,3.3,1H),1.86–1.80(m,1H),1.73–1.68(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C28H29O7 –477.1919,found 477.1919.
Data for 28:1H NMR(600MHz,Acetone-d6)δ＝8.38–8.34(m,2H),8.10–8.05(m,2H),6.18(s,1H),5.97(s,1H),5.69(s,1H),5.01(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.64(dt,J＝14.2,3.7,1H),4.22(d,J＝3.7,1H),3.59(d,J＝3.8,1H),2.93(dd,J＝11.7,3.3,1H),2.60–2.59(m,1H),2.57–2.50(m,1H),2.26(dd,J＝13.9,11.8,1H),2.03–2.00(m,2H),1.92(dd,J＝13.9,3.3,1H),1.88–1.80(m,1H),1.76–1.70(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C28H26F3O7 –531.1636,found 531.1629.
Figure BDA0003586979280000132
Data for 29:1H NMR(800MHz,Acetone-d6)δ＝8.43(d,J＝5.1,1H),7.63(dt,J＝5.1,1.5,1H),7.34(s,1H),6.18(s,1H),5.96(d,J＝1.4,1H),5.68(d,J＝1.0,1H),4.99(d,J＝10.8,1H),4.92(d,J＝10.7,1H),4.63–4.60(m,1H),4.24(d,J＝3.6,1H),3.58(s,1H),2.93(dd,J＝11.8,3.4,1H),2.62–2.60(m,1H),2.55–2.51(m,1H),2.26(dd,J＝13.9,11.7,1H),2.04–2.00(m,2H),1.92(dd,J＝13.9,3.4,1H),1.87–1.81(m,1H),1.76–1.71(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C26H25FNO7 –482.1621,found482.1623.
Data for 30:1H NMR(800MHz,Acetone-d6)δ＝8.66(d,J＝2.3,1H),8.58(d,J＝4.8,1H),7.62(dd,J＝6.1,4.9,1H),6.15(s,1H),5.99(d,J＝1.5,1H),5.67(d,J＝1.0,1H),4.98(d,J＝10.7,1H),4.91(d,J＝10.7,1H),4.60(dd,J＝14.2,3.6,1H),4.23(d,J＝3.7,1H),3.54(s,1H),2.93(dd,J＝11.7,3.4,1H),2.60–2.58(m,1H),2.56–2.50(m,1H),2.26(dd,J＝13.9,11.8,1H),2.01(dd,J＝7.5,3.5,2H),1.92(dd,J＝13.9,3.4,1H),1.86–1.80(m,1H),1.76–1.71(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd forC26H25FNO7 –482.1621,found 482.1624.
Figure BDA0003586979280000141
Data for 31:1H NMR(600MHz,Acetone-d6)δ＝8.60(d,J＝5.0,1H),7.68(dd,J＝6.6,1.5,2H),6.18(s,1H),5.96(d,J＝1.5,1H),5.68(s,1H),5.62(d,J＝1.7,1H),4.98(d,J＝10.8,1H),4.91(d,J＝10.8,1H),4.61(dd,J＝14.2,3.4,1H),4.25(d,J＝3.6,1H),3.58(t,J＝3.7,1H),2.93(dd,J＝11.7,3.3,1H),2.64–2.59(m,1H),2.57–2.48(m,1H),2.26(dd,J＝13.9,11.7,1H),2.03–1.99(m,1H),1.92(dd,J＝13.8,3.3,1H),1.84(ddt,J＝16.4,8.6,4.5,1H),1.73(ddt,J＝15.8,6.6,3.0,1H),1.25(s,3H),1.22(d,J＝2.7,3H)；HRESIMS(m/z):[M–H]–calcd for C26H25ClNO7 –498.1325,found 498.1325.
Data for 32:1H NMR(600MHz,Acetone-d6)δ＝8.71(s,1H),8.65(d,J＝4.9,1H),7.57(d,J＝4.9,1H),6.13(s,1H),6.00(s,1H),5.65(s,1H),4.99(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.61(dd,J＝14.2,3.5,1H),4.30(dt,J＝3.4,1.6,1H),3.54(d,J＝4.1,1H),2.93(dd,J＝11.8,3.3,1H),2.62–2.58(m,1H),2.57–2.51(m,1H),2.25(dd,J＝13.8,11.7,1H),2.03–1.98(m,2H),1.91(dd,J＝13.8,3.3,1H),1.86–1.79(m,1H),1.76–1.70(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C26H25ClNO7 –498.1325,found498.1324.
Figure BDA0003586979280000142
Data for 33:1HNMR(600MHz,Acetone-d6)δ＝8.84(d,J＝2.4,1H),8.68(dd,J＝5.4,2.3,1H),7.55(d,J＝4.7,1H),6.13(s,1H),6.00(s,1H),5.65(d,J＝2.5,1H),4.99(dd,J＝10.8,2.4,1H),4.94(dd,J＝10.8,2.5,1H),4.64–4.57(m,1H),4.34(s,1H),3.54(s,1H),2.95–2.92(m,1H),2.60(d,J＝7.9,1H),2.57–2.51(m,1H),2.29–2.21(m,1H),2.02–1.97(m,2H),1.91(dd,J＝13.8,3.2,1H),1.86–1.77(m,1H),1.75–1.69(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+K]+calcd for C26H26BrNO7K+582.0524,found582.0528.
Data for 34:1H NMR(600MHz,Acetone-d6)δ＝8.58(d,J＝5.0,1H),7.82(d,J＝1.4,1H),7.70(dd,J＝5.0,1.3,1H),6.17(s,1H),5.94(s,1H),5.68(s,1H),4.98(d,J＝10.8,1H),4.91(d,J＝10.8,1H),4.60(dd,J＝14.3,3.2,1H),4.31(d,J＝3.4,1H),3.58–3.55(m,1H),2.95–2.92(m,1H),2.60–2.59(m,1H),2.55–2.48(m,1H),2.28–2.22(m,1H),2.03–1.99(m,2H),1.90(dd,J＝13.9,3.3,1H),1.85–1.79(m,1H),1.74–1.68(m,1H),1.23(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+K]+calcd for C26H26BrNO7K+582.0524,found582.0527.
Figure BDA0003586979280000151
Data for 35:1H NMR(600MHz,Acetone-d6)δ＝7.29–7.25(m,2H),7.21–7.17(m,3H),6.09(s,1H),5.67(d,J＝1.4,1H),5.58(s,1H),4.92(d,J＝10.8,1H),4.86(d,J＝10.8,1H),4.51(dd,J＝14.3,3.5,1H),4.07(d,J＝3.5,1H),3.28(d,J＝4.1,1H),2.91–2.88(m,1H),2.82–2.79(m,2H),2.57–2.45(m,3H),2.45–2.40(m,1H),2.23(dd,J＝13.8,11.7,1H),1.98–1.92(m,2H),1.90(dd,J＝13.9,3.3,1H),1.81–1.73(m,1H),1.67–1.62(m,1H),1.24(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H32O7Na+515.2046,found 515.2040.
Data for 36:1H NMR(600MHz,Acetone-d6)δ＝7.70–7.64(m,2H),7.58(d,J＝16.0,1H),7.44(dd,J＝5.1,1.9,3H),6.41(d,J＝16.0,1H),6.14(s,1H),5.79(d,J＝1.4,1H),5.64(d,J＝1.0,1H),4.98(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.61(dd,J＝14.3,3.5,1H),4.13(d,J＝3.5,1H),3.45–3.40(m,1H),2.90(dd,J＝11.7,3.3,1H),2.53(dd,J＝9.2,2.6,1H),2.51–2.45(m,1H),2.25(dd,J＝13.9,11.7,1H),2.02–1.95(m,2H),1.91(dd,J＝13.8,3.4,1H),1.85–1.77(m,1H),1.71–1.65(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H30O7Na+513.1893,found 513.1884.
Figure BDA0003586979280000152
Data for 37:1HNMR(600MHz,Acetone-d6)δ＝7.52–7.49(m,1H),7.45–7.36(m,5H),6.14(s,1H),5.77(d,J＝1.4,1H),5.66–5.62(m,1H),5.00(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.63(dd,J＝14.2,3.6,1H),4.16(d,J＝3.7,1H),3.47(d,J＝3.9,1H),2.92(d,J＝3.4,1H),2.54(dd,J＝9.1,2.4,1H),2.51–2.45(m,1H),2.25(dd,J＝13.8,11.8,1H),2.02–1.99(m,2H),1.99–1.98(m,3H),1.92(dd,J＝13.9,3.4,1H),1.86–1.77(m,1H),1.72–1.66(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C30H32O7Na+527.2040,found 527.2049.
Data for 38:1H NMR(600MHz,Acetone-d6)δ＝7.81–7.74(m,2H),7.57(d,J＝16.0,1H),7.21(t,J＝8.7,2H),6.37(d,J＝16.0,1H),6.13(s,1H),5.79(s,1H),5.64(s,1H),4.97(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.60(dd,J＝14.3,3.3,1H),4.12(d,J＝3.6,1H),3.42(s,1H),2.91(d,J＝3.3,1H),2.53(dd,J＝9.2,2.6,1H),2.51–2.44(m,1H),2.25(dd,J＝13.8,11.8,1H),2.01–1.95(m,2H),1.91(dd,J＝13.9,3.3,1H),1.85–1.76(m,1H),1.71–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd forC29H29FO7Na+531.1790,found 531.1793.
Figure BDA0003586979280000161
Data for 39:1HNMR(600MHz,Acetone-d6)δ＝7.72(d,J＝8.4,2H),7.56(d,J＝16.0,1H),7.50–7.43(m,2H),6.43(d,J＝16.0,1H),6.13(s,1H),5.79(d,J＝1.4,1H),5.64(s,1H),4.97(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.60(dd,J＝14.3,3.2,1H),4.13(d,J＝3.6,1H),3.42(d,J＝4.1,1H),2.92–2.90(m,1H),2.53(dd,J＝9.1,2.6,1H),2.51–2.44(m,1H),2.25(dd,J＝13.9,11.8,1H),2.01–1.95(m,2H),1.91(dd,J＝13.9,3.3,1H),1.84–1.77(m,1H),1.71–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcdfor C29H29ClO7Na+547.1494,found 547.1499.
Data for 40:1H NMR(600MHz,Acetone-d6)δ＝7.65(d,J＝8.6,2H),7.62(d,J＝8.6,2H),7.55(d,J＝16.0,1H),6.45(d,J＝16.0,1H),6.13(s,1H),5.79(d,J＝1.4,1H),5.64(s,1H),4.97(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.60(dd,J＝14.3,3.6,1H),4.13(d,J＝3.6,1H),3.42(d,J＝3.9,1H),2.90(dd,J＝11.7,3.4,1H),2.53(dd,J＝9.2,2.6,1H),2.51–2.44(m,1H),2.25(dd,J＝13.9,11.7,1H),2.01–1.95(m,2H),1.91(dd,J＝13.9,3.3,1H),1.84–1.76(m,1H),1.71–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H29BrO7Na+591.0989,found 591.0990.
Figure BDA0003586979280000162
Data for 41:1H NMR(600MHz,Acetone-d6)δ＝8.31–8.26(m,2H),8.01–7.97(m,2H),7.68(d,J＝16.1,1H),6.64(d,J＝16.0,1H),6.14(s,1H),5.82(d,J＝1.4,1H),5.65(t,J＝1.0,1H),4.97(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.60(dd,J＝14.3,3.7,1H),4.14(d,J＝3.7,1H),3.44(s,1H),2.93–2.90(m,1H),2.54(dd,J＝9.1,2.7,1H),2.52–2.46(m,1H),2.25(dd,J＝13.9,11.7,1H),2.02–1.96(m,2H),1.92(dd,J＝13.9,3.3,1H),1.85–1.77(m,1H),1.72–1.66(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcdfor C29H29NO9Na+558.1735,found 558.1735.
Figure BDA0003586979280000171
Data for 42:1HNMR(600MHz,Acetone-d6)δ＝7.65–7.59(m,2H),7.52(d,J＝15.9,1H),7.00–6.96(m,2H),6.23(d,J＝15.9,1H),6.12(s,1H),5.76(d,J＝1.4,1H),5.62(d,J＝1.1,1H),4.96(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.60(dd,J＝14.3,3.6,1H),4.11(d,J＝3.6,1H),3.84(s,3H),3.39(d,J＝3.9,1H),2.91–2.88(m,1H),2.51(dd,J＝9.2,2.6,1H),2.48–2.43(m,1H),2.23(dd,J＝13.9,11.8,1H),2.00–1.93(m,2H),1.92–1.88(m,1H),1.83–1.75(m,1H),1.69–1.64(m,1H),1.24(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C30H32O8Na+543.1995,found 543.1989.
Data for 43:1H NMR(600MHz,Acetone-d6)δ＝7.58–7.52(m,3H),7.25(d,J＝7.9,2H),6.34(d,J＝16.0,1H),6.13(s,1H),5.78(d,J＝1.4,1H),5.64(d,J＝1.1,1H),4.97(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.61(dd,J＝14.3,3.6,1H),4.13(d,J＝3.6,1H),3.43–3.40(m,1H),2.92–2.89(m,1H),2.52(dd,J＝9.2,2.6,1H),2.50–2.44(m,1H),2.36(s,3H),2.25(dd,J＝13.9,11.8,1H),2.01–1.95(m,2H),1.91(dd,J＝13.9,3.4,1H),1.83–1.77(m,1H),1.70–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcdfor C30H32O7Na+527.2040,found527.2035.
Figure BDA0003586979280000172
Data for 44:1H NMR(600MHz,Acetone-d6)δ＝7.51(d,J＝15.9,1H),7.33(d,J＝2.0,1H),7.17(dd,J＝8.3,2.0,1H),6.98(d,J＝8.3,1H),6.28(d,J＝15.9,1H),6.13(s,1H),5.77(d,J＝1.3,1H),5.64(s,1H),4.95(q,J＝10.8,2H),4.61(dd,J＝14.3,3.6,1H),4.12(d,J＝3.6,1H),3.87(s,3H),3.86(s,3H),3.40(s,1H),2.92–2.89(m,1H),2.52(dd,J＝9.1,2.4,1H),2.50–2.44(m,1H),2.24(dd,J＝13.9,11.8,1H),2.01–1.93(m,2H),1.91(dd,J＝13.9,3.3,1H),1.84–1.76(m,1H),1.70–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C31H34O9Na+573.2095,found 573.2091.
Data for 45:1H NMR(600MHz,Acetone-d6)δ＝7.99(s,1H),7.64(d,J＝1.9,1H),7.51(d,J＝15.8,1H),6.91(d,J＝1.9,1H),6.16–6.11(m,2H),5.76(s,1H),5.64–5.62(m,1H),4.99–4.90(m,2H),4.59(dd,J＝14.3,3.6,1H),4.11(d,J＝3.4,1H),3.42–3.37(m,1H),2.92–2.89(m,1H),2.51(dd,J＝9.3,2.6,1H),2.50–2.44(m,1H),2.24(dd,J＝13.8,11.7,1H),1.97(dd,J＝17.4,13.0,2H),1.91(dd,J＝13.9,3.3,1H),1.83–1.76(m,1H),1.71–1.65(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C27H28O8Na+503.1686,found 503.1676.
Figure BDA0003586979280000181
Data for 46:1H NMR(600MHz,Acetone-d6)δ＝8.65(d,J＝5.2,2H),7.64–7.59(m,2H),7.53(d,J＝16.1,1H),6.65(d,J＝16.0,1H),6.14(s,1H),5.81(d,J＝1.4,1H),5.65(t,J＝1.0,1H),4.97(d,J＝10.8,1H),4.92(d,J＝10.8,1H),4.60(dd,J＝14.3,3.6,1H),4.23–4.18(m,1H),3.44(s,1H),2.94–2.90(m,1H),2.54(dd,J＝9.1,2.7,1H),2.53–2.44(m,1H),2.25(dd,J＝13.9,11.7,1H),2.03–1.95(m,2H),1.91(dd,J＝13.9,3.3,1H),1.86–1.75(m,1H),1.72–1.64(m,1H),1.25(s,3H),1.22(s,4H)；HRESIMS(m/z):[M+H]+calcd forC27H30NO7 +492.2018,found 492.2017.
Data for 47:1H NMR(600MHz,Acetone-d6)δ＝7.22–7.15(m,2H),7.15–7.09(m,2H),6.11(s,1H),5.70(s,1H),5.61(s,1H),4.98–4.91(m,1H),4.91–4.85(m,1H),4.59–4.52(m,1H),4.18–4.13(m,1H),3.37(s,1H),3.25–3.18(m,1H),3.12–3.04(m,4H),2.92–2.88(m,1H),2.54–2.49(m,1H),2.49–2.41(m,1H),2.28–2.20(m,1H),2.00–1.93(m,2H),1.92–1.88(m,1H),1.84–1.74(m,1H),1.69–1.63(m,1H),1.23(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C30H32O7Na+537.1884,found 537.1893.
Figure BDA0003586979280000182
Data for 48:1HNMR(600MHz,Acetone-d6)δ＝7.86–7.79(m,1H),7.63(d,J＝8.4,1H),7.57–7.50(m,2H),7.38(t,J＝7.4,1H),6.18(s,1H),5.95(s,1H),5.73–5.67(m,1H),5.01(d,J＝10.8,1H),4.95(d,J＝10.7,1H),4.65(dd,J＝14.2,3.5,1H),4.23(d,J＝3.6,1H),3.56(d,J＝3.8,1H),2.93(dd,J＝11.8,3.3,1H),2.60–2.57(m,1H),2.56–2.50(m,1H),2.26(dd,J＝13.8,11.8,1H),2.04–1.98(m,2H),1.92(dd,J＝14.0,3.3,1H),1.88–1.79(m,1H),1.75–1.69(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+K]+calcd forC29H28O8K+543.1416,found543.1426.
Data for 49:1H NMR(600MHz,Acetone-d6)δ＝7.69(d,J＝8.1,1H),7.48(d,J＝8.3,1H),7.31–7.27(m,1H),7.13–7.08(m,1H),7.06(d,J＝2.2,1H),6.17(s,1H),5.92(s,1H),5.67(s,1H),5.01(d,J＝10.8,1H),4.97(d,J＝10.8,1H),4.65(dd,J＝14.2,3.6,1H),4.14(dd,J＝3.6,1.5,1H),3.55–3.51(m,1H),2.92(dd,J＝11.7,3.3,1H),2.56(dd,J＝9.2,2.6,1H),2.54–2.48(m,1H),2.26(dd,J＝13.9,11.8,1H),2.03–1.97(m,2H),1.92(dd,J＝13.9,3.3,1H),1.87–1.80(m,1H),1.73–1.68(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H29NO7Na+526.1836,found 526.1839.
Figure BDA0003586979280000191
Data for 50:1H NMR(600MHz,Acetone-d6)δ＝8.03(d,J＝8.1,1.3,2H),8.00(s,1H),7.57–7.52(m,1H),7.51–7.46(m,1H),6.19(s,1H),5.92(s,1H),5.69(s,1H),5.02(d,J＝10.8,1H),4.94(d,J＝10.8,1H),4.66(dd,J＝14.2,3.4,1H),4.21(d,J＝3.4,1H),3.56(s,1H),2.95–2.92(m,1H),2.58(dd,J＝9.2,2.7,1H),2.56–2.49(m,1H),2.26(dd,J＝13.9,11.8,1H),2.04–1.98(m,2H),1.92(dd,J＝13.9,3.3,1H),1.87–1.79(m,1H),1.75–1.69(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H28O7SNa+543.1448,found 543.1449.
Data for 51:1H NMR(800MHz,Acetone-d6)δ＝8.56(d,J＝6.9,1H),8.22(s,1H),7.56(d,J＝9.2,1H),7.38–7.31(m,1H),6.99(t,J＝6.7,1H),6.16(s,1H),5.90(s,1H),5.66(s,1H),5.02(d,J＝10.8,1H),4.98(d,J＝10.8,1H),4.67(dd,J＝14.2,3.5,1H),4.15(d,J＝3.6,1H),3.51(s,1H),2.93–2.91(m,1H),2.56(dd,J＝9.1,2.5,1H),2.54–2.50(m,1H),2.25(dd,J＝13.9,11.8,1H),1.99–1.96(m,2H),1.92(dd,J＝13.9,3.4,1H),1.86–1.80(m,1H),1.73–1.69(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcdfor C28H28N2O7Na+527.1792,found527.1789.
Figure BDA0003586979280000192
Data for 52:1HNMR(600MHz,Acetone-d6)δ＝9.08(dd,J＝7.0,1.8,1H),8.80(dd,J＝4.1,1.8,1H),8.31(s,1H),7.30(dd,J＝7.0,4.1,1H),6.16(s,1H),5.88(s,1H),5.65(s,1H),5.04(d,J＝10.8,1H),4.99(d,J＝10.8,1H),4.70(dd,J＝14.3,3.6,1H),4.10(d,J＝3.4,1H),3.52(s,1H),2.93–2.92(m,1H),2.55(dd,J＝9.3,2.5,1H),2.53–2.48(m,1H),2.26(dd,J＝13.8,11.8,1H),2.03–1.96(m,2H),1.92(dd,J＝13.8,3.4,1H),1.87–1.79(m,1H),1.74–1.68(m,1H),1.27(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd forC27H27N3O7Na+528.1741,found528.1738.
Data for 53:1H NMR(600MHz,Acetone-d6)δ＝8.56(s,1H),6.15(s,1H),6.01(d,J＝1.4,1H),5.67(s,1H),5.01(d,J＝10.8,1H),4.95(d,J＝10.8,1H),4.66(dd,J＝14.2,3.9,1H),4.09(d,J＝3.9,1H),3.98(s,3H),3.53–3.50(m,1H),2.95–2.92(m,1H),2.57(dd,J＝9.2,3.2,1H),2.56–2.51(m,1H),2.26(dd,J＝13.8,11.8,1H),2.03–1.98(m,2H),1.93(dd,J＝13.9,3.4,1H),1.88–1.80(m,1H),1.76–1.70(m,1H),1.28(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C26H27N5O8Na+560.1752,found 560.1744.
Figure BDA0003586979280000201
Data for 54:1H NMR(600MHz,Acetone-d6)δ＝8.48–8.45(m,1H),8.05(d,J＝8.2,1H),7.99(dd,J＝8.5,4.3,2H),7.85(dd,J＝8.6,1.7,1H),7.68(ddd,J＝8.2,6.8,1.3,1H),7.62(ddd,J＝8.1,6.8,1.3,1H),6.20(s,1H),5.96(s,1H),5.69(t,J＝1.0,1H),5.05(d,J＝10.8,1H),5.00(d,J＝10.8,1H),4.70(dd,J＝14.3,3.6,1H),4.20(d,J＝3.5,1H),3.58(d,J＝3.9,1H),2.94(dd,J＝11.7,3.3,1H),2.60–2.58(m,1H),2.57–2.51(m,1H),2.27(dd,J＝13.8,11.8,1H),2.04–1.99(m,2H),1.93(dd,J＝13.9,3.4,1H),1.89–1.81(m,1H),1.76–1.70(m,1H),1.27(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+Na]+calcd forC31H30O7Na+537.1884,found 537.1893.
Data for 55:1H NMR(600MHz,Acetone-d6)δ＝7.34–7.32(m,1H),7.31–7.25(m,2H),6.99–6.95(m,1H),6.83(d,J＝8.1,1H),6.14(s,1H),5.79(s,1H),5.64(s,1H),4.98(d,J＝10.8,1H),4.91(d,J＝10.8,1H),4.81(t,J＝1.7,2H),4.60(dd,J＝14.2,3.3,1H),4.21(d,J＝3.4,1H),3.47(d,J＝3.9,1H),2.90(dd,J＝11.7,3.3,1H),2.54(dd,J＝9.1,2.6,1H),2.51–2.45(m,1H),2.25(dd,J＝13.9,11.7,1H),2.02–1.97(m,2H),1.91(dd,J＝13.9,3.4,1H),1.84–1.78(m,1H),1.71–1.66(m,1H),1.25(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+H]+calcd for C30H31O8 +519.2013,found 519.2017.
Figure BDA0003586979280000202
Data for 56:1H NMR(600MHz,Acetone-d6)δ＝8.53–8.48(m,1H),8.16–8.11(m,1H),8.08–8.04(m,1H),7.95–7.91(m,1H),7.90–7.84(m,1H),7.78–7.72(m,1H),6.19(s,1H),6.03(s,1H),5.70(s,1H),5.08–4.97(m,2H),4.73–4.66(m,1H),4.20(s,1H),3.61(s,1H),2.97–2.92(m,1H),2.60–2.54(m,2H),2.31–2.23(m,1H),2.10–2.08(m,2H),1.96–1.91(m,1H),1.90–1.83(m,1H),1.79–1.72(m,1H),1.28(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C30H29NO7Na+538.1836,found 538.1842.
Data for 57:1H NMR(600MHz,Acetone-d6)δ＝9.25(s,1H),8.21–8.17(m,2H),8.05–8.01(m,1H),8.00–7.96(m,1H),6.21(s,1H),6.09(s,1H),5.72(s,1H),5.03(d,1H),4.99(d,J＝10.8,1H),4.68(dd,J＝14.2,3.4,1H),4.29(d,J＝3.5,1H),3.65(d,J＝3.9,1H),2.95(dd,J＝11.8,3.3,1H),2.63(dd,J＝9.1,3.1,1H),2.60–2.55(m,1H),2.28(dd,J＝13.8,11.8,1H),2.09–2.06(m,2H),1.95–1.92(m,1H),1.88–1.83(m,1H),1.79–1.74(m,1H),1.28(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C29H28N2O7Na+539.1789,found 539.1794.
Figure BDA0003586979280000211
Data for 58:1H NMR(600MHz,Acetone-d6)δ＝7.57(dt,J＝7.7,1.3,1H),7.49(t,J＝8.0,1H),7.46–7.42(m,2H),7.41(dd,J＝2.6,1.5,1H),7.25(ddd,J＝8.2,2.6,1.1,1H),7.23–7.20(m,1H),7.07–7.04(m,2H),6.13(s,1H),5.87(s,1H),5.63(s,1H),5.00(d,J＝10.8,1H),4.93(d,J＝10.8,1H),4.63(dd,J＝14.3,3.6,1H),4.16(d,J＝3.6,1H),3.51(s,1H),2.94–2.91(m,1H),2.56(dd,J＝9.2,2.6,1H),2.52–2.46(m,1H),2.25(dd,J＝13.8,11.7,1H),2.03–1.97(m,2H),1.91(dd,J＝13.9,3.3,1H),1.85–1.79(m,1H),1.72–1.67(m,1H),1.25(s,3H),1.21(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C33H32O8Na+579.1989,found579.1985.
Data for 59:1H NMR(600MHz,Acetone-d6)δ＝8.11(d,J＝5.1,1H),7.94(d,J＝7.8,1H),7.82(d,J＝7.7,1H),7.67(d,J＝7.7,2H),7.59(t,J＝7.8,1H),7.51(t,J＝7.7,2H),7.42(t,J＝7.4,1H),6.16(s,1H),5.92(s,1H),5.67(s,1H),5.03(d,J＝10.6,1H),5.01–4.95(m,1H),4.73–4.63(m,1H),4.22(s,1H),3.60–3.54(m,1H),2.96–2.92(m,1H),2.61–2.57(m,1H),2.56–2.50(m,1H),2.29–2.22(m,1H),2.03–1.98(m,2H),1.95–1.91(m,1H),1.88–1.80(m,1H),1.75–1.69(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M–H]–calcd for C33H31O7 –539.2075,found 539.2084.
Figure BDA0003586979280000212
Data for 60:1H NMR(600MHz,Acetone-d6)δ＝8.69(d,J＝4.8,2H),7.99–7.95(m,2H),7.92–7.88(m,2H),7.74–7.69(m,2H),6.18(s,1H),5.94(s,1H),5.68(s,1H),5.03(d,J＝10.8,1H),4.97(d,J＝10.8,1H),4.67(dd,J＝14.2,3.6,1H),4.18(d,J＝3.6,1H),3.57(d,J＝3.9,1H),2.93(dd,J＝11.7,3.3,1H),2.59(dd,J＝9.5,2.9,1H),2.56–2.50(m,1H),2.27(dd,J＝13.9,11.8,1H),2.04–2.00(m,2H),1.93(dd,J＝13.9,3.4,1H),1.89–1.81(m,1H),1.76–1.69(m,1H),1.27(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+H]+calcd forC32H32NO7 +542.2173,found542.2180.
Data for 61:1H NMR(600MHz,Acetone-d6)δ＝7.79–7.74(m,2H),7.27(t,J＝7.5,2H),7.25–7.21(m,2H),7.19–7.14(m,1H),7.01–6.96(m,2H),6.15(s,1H),5.84(s,1H),5.64(s,1H),5.01(d,J＝10.8,1H),4.96(d,J＝10.8,1H),4.65(dd,J＝14.3,3.6,1H),4.15–4.06(m,3H),3.50(s,1H),2.91(dd,J＝11.8,3.4,1H),2.70(t,J＝7.1,2H),2.56–2.53(m,1H),2.53–2.46(m,1H),2.25(dd,J＝13.9,11.7,1H),2.03–1.96(m,2H),1.94–1.89(m,1H),1.86–1.77(m,5H),1.72–1.67(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+K]+calcd for C37H40O8K+651.2355,found 651.2352.
Figure BDA0003586979280000221
Data for 62:1H NMR(600MHz,Acetone-d6)δ＝9.19(s,1H),9.10–9.07(m,2H),8.18(d,J＝2.1,1H),8.08–8.05(m,1H),7.96–7.91(m,1H),7.69(t,J＝7.8,1H),6.17(s,1H),5.93(s,1H),5.67(s,1H),5.03(d,J＝10.7,1H),4.97(d,J＝10.8,1H),4.68(dd,J＝14.3,3.6,1H),4.19(dd,J＝3.7,1.4,1H),3.59(s,1H),2.93(dd,J＝11.7,3.3,1H),2.59(d,J＝9.3,1H),2.57–2.50(m,1H),2.27(dd,J＝13.9,11.8,1H),2.04–2.00(m,2H),1.93(dd,J＝13.9,3.3,1H),1.89–1.81(m,1H),1.76–1.69(m,1H),1.26(s,3H),1.23(s,3H)；HRESIMS(m/z):[M+Na]+calcd for C31H30N2O7Na+565.1945,found 565.1936.
Data for 63:1H NMR(600MHz,Acetone-d6)δ＝9.13(d,J＝2.6,1H),8.80(s,1H),8.61(dd,J＝4.7,1.5,1H),8.26(ddd,J＝8.4,2.7,1.4,1H),7.98(s,1H),7.56(dd,J＝8.3,4.7,1H),6.15(s,1H),5.86(s,1H),5.65(s,1H),5.00(d,J＝10.8,1H),4.95(d,J＝10.8,1H),4.65(dd,J＝14.3,3.2,1H),4.14(d,J＝3.5,1H),3.50(s,1H),2.91(dd,J＝11.7,3.4,1H),2.56(dd,J＝9.2,2.5,1H),2.54–2.47(m,1H),2.26(dd,J＝13.9,11.8,1H),2.04–1.97(m,2H),1.92(dd,J＝13.9,3.4,1H),1.87–1.78(m,1H),1.73–1.67(m,1H),1.26(s,3H),1.22(s,3H)；HRESIMS(m/z):[M+H]+calcd for C29H30N3O7 +532.2078,found 532.2086.
实施例3
细胞毒实验流程：
(1)实验材料
细胞株：人正常肝细胞(LO2)，宫颈癌细胞株(Hela)，卵巢癌细胞株(SK-OV-3)，肝癌细胞株(SK-HEP-1)，结肠癌株(CACO2)，乳腺癌细胞株(MDA-MB-231)，前列腺癌细胞株(PC-3)，结肠癌细胞株(SW480)，人肺癌紫杉醇耐药株(A549/Taxol)等九株细胞。
(2)实验原理
MTS为一种全新的MTT类似物，全称为3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazoliu-m，是一种黄色染料。活细胞线粒体中琥珀酸脱氢酶能够代谢还原MTS，生成可溶性的甲臜(Formazan)化合物，其含量可用酶标仪在490nm处进行测定。在通常情况下，甲臜生成量与活细胞数成正比，据此可根据光密度OD值推测出活细胞的数目。
(3)实验方法：MTS法检测细胞活性。
①接种细胞：用含10％胎牛血清的培养液(DMEM或者RMPI1640)配成单个细胞悬液，以每孔3000～15000个细胞接种到96孔板，每孔体积100μL，贴壁细胞提前12～24h接种培养。
②加入待测化合物溶液：化合物用DMSO溶解，化合物用DMSO溶解，化合物以40μM、8μM、1.6μM、0.32μM、0.064μM浓度复筛，每孔终体积200μL，每种处理均设3个复孔。
③显色：37℃培养48h后，贴壁细胞弃孔内培养液，每孔加MTS溶液20μL以及培养液100μL；悬浮细胞弃100μL培养上清液，每孔加20μL的MTS溶液；设3个空白复孔(MTS溶液20μL和培养液100μL的混合液)，继续孵育2～4h，使反应充分进行。
④比色：选择492nm波长，多功能酶标仪(MULTISKAN FC)读取各孔光吸收值，记录结果，以浓度为横坐标，细胞存活率为纵坐标绘制细胞生长曲线，应用两点法(Reed andMuench法)计算化合物的IC50值。
⑤阳性对照物：每次实验均设顺铂(DDP)和紫杉醇(Taxol)两个阳性化合物，以浓度为横坐标，细胞存活率为纵坐标绘制细胞生长曲线，应用两点法(Reed and Muench法)计算化合物的IC50值。
(4)实验结果见图1。
本发明的毛萼内酯素B衍生物对人宫颈癌细胞株(Hela)，卵巢癌细胞株(SK-OV-3)，肝癌细胞株(SK-HEP-1)，结肠癌株(CACO2)，乳腺癌细胞株(MDA-MB-231)，前列腺癌细胞株(PC-3)，结肠癌细胞株(SW480)，人肺癌紫杉醇耐药株(A549/Taxol)都有较好的抑制作用。
制剂实施例
在以下制剂实施例中，选择常规试剂，并按照现有常规方法进行制剂制备，本应用例仅体现本发明所述毛萼内酯素B衍生物制备成不同的制剂，对具体试剂和操作不作具体限定。
1.将毛萼内酯素B衍生物任其一或任其组合用DMSO溶解后，按常规方法加注射用水，精滤，灌封灭菌制成注射液，所述注射液的浓度为0.5～5mg/mL。
2.将毛萼内酯素B衍生物任其一或任其组合用DMSO溶解后，将其溶于无菌注射用水中，搅拌使其溶解，用无菌抽滤漏斗过滤，再无菌精滤，分装于安瓿中，低温冷冻干燥后无菌熔封，得粉针剂。
3.将毛萼内酯素B衍生物任其一或任其组合按其与赋形剂质量比为9:1的比例加入赋形剂，制成粉剂。
4.将毛萼内酯素B衍生物任其一或任其组合按其与赋形剂质量比为5:1的比例加入赋形剂，制粒压片。
5.将毛萼内酯素B衍生物任其一或任其组合按常规口服液制备方法制成口服液。
6.将毛萼内酯素B衍生物任其一或任其组合按其与赋形剂质量比为5:1的比例加入赋形剂，制成胶囊。
7.将毛萼内酯素B衍生物任其一或任其组合按其与赋形剂质量比为5:1的比例加入赋形剂，制成颗粒剂。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。

Claims (9)

1.如下结构式所示的毛萼内酯素B衍生物，
Figure FDA0003586979270000011
其中R为以下官能团：
Figure FDA0003586979270000012
2.权利要求1所述的毛萼内酯素B衍生物的制备方法，其特征在于，该方法以毛萼内酯素B为起始原料，通过酯化反应得到毛萼内酯素B衍生物，
Figure FDA0003586979270000013
该方法包括如下步骤：氩气保护下，将毛萼内酯素B溶解在0.1～0.5mL的二氯甲烷中，加入EDCI及DMAP，将反应置于室温中反应1～12个小时，TLC检测反应完全后，饱和NaHCO3淬灭，EtOAc萃取，饱和食盐水洗涤、无水MgSO4干燥，过滤，浓缩后柱层析纯化或经过制备纯化，分离得到毛萼内酯素B衍生物。
3.权利要求1所述的毛萼内酯素B衍生物在制备抗肿瘤药物中的应用。
4.权利要求1所述的毛萼内酯素B衍生物在制备宫颈癌、结肠癌、卵巢癌、肺癌、前列腺癌、乳腺癌、肝癌的药物中的应用。
5.药物组合物，含有权利要求1所述的毛萼内酯素B衍生物任其一或任其组合及可药用载体。
6.根据权利要求5所述的药物组合物，其特征在于抗肿瘤药物的剂型为粉剂、颗粒剂、片剂、胶囊剂、丸剂、溶液、悬浮液或注射液。
7.权利要求5所述的药物组合物的制备方法，其特征在于该方法以毛萼内酯素B为起始原料，通过酯化反应得到毛萼内酯素B衍生物，然后再加入可药用载体，
Figure FDA0003586979270000021
该方法包括如下步骤：氩气保护下，将毛萼内酯素B溶解在0.1～0.5mL的二氯甲烷中，加入EDCI及DMAP，将反应置于室温中反应1～12个小时，TLC检测反应完全后，饱和NaHCO3淬灭，EtOAc萃取，饱和食盐水洗涤、无水MgSO4干燥，过滤，浓缩后柱层析纯化或经过制备纯化，分离得到毛萼内酯素B衍生物，然后再加入可药用载体。
8.权利要求5所述的药物组合物在制备抗肿瘤药物中的应用。
9.权利要求5所述的药物组合物在制备宫颈癌、结肠癌、卵巢癌、肺癌、前列腺癌、乳腺癌、肝癌的药物中的应用。
CN202210370822.3A 2022-04-08 2022-04-08 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用 Active CN114805269B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210370822.3A CN114805269B (zh) 2022-04-08 2022-04-08 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210370822.3A CN114805269B (zh) 2022-04-08 2022-04-08 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用

Publications (2)

Publication Number Publication Date
CN114805269A true CN114805269A (zh) 2022-07-29
CN114805269B CN114805269B (zh) 2023-09-15

Family

ID=82535220

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210370822.3A Active CN114805269B (zh) 2022-04-08 2022-04-08 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用

Country Status (1)

Country Link
CN (1) CN114805269B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114890971A (zh) * 2022-04-08 2022-08-12 中国科学院昆明植物研究所 毛萼内酯素b衍生物及其药物组合物与抗新冠肺炎的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769886A (ja) * 1993-09-03 1995-03-14 Lotte Co Ltd 抗う蝕、歯周病剤およびこれを含有する口腔用組成物
KR20030003215A (ko) * 2002-12-23 2003-01-09 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도
US20040048918A1 (en) * 2000-12-12 2004-03-11 Jung-Joon Lee Novel use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer
CN102002051A (zh) * 2010-10-18 2011-04-06 中国药科大学 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途
CN102229598A (zh) * 2011-04-21 2011-11-02 新乡医学院 一种对映-贝壳杉型二萜类化合物及其制备方法和应用
CN103145726A (zh) * 2013-02-26 2013-06-12 中国科学院昆明植物研究所 一种对映-贝壳杉烷二萜化合物及其药物组合物和应用
CN103467474A (zh) * 2013-09-17 2013-12-25 中国药科大学 1,6,7,14-位取代的冬凌草甲素衍生物、制备方法及用途
WO2018059372A1 (en) * 2016-09-27 2018-04-05 Hong Kong Baptist University Method of use of diterpenoid derivatives as anticancer agents
CN108299458A (zh) * 2017-12-28 2018-07-20 青岛海洋生物医药研究院股份有限公司 冬凌草甲素衍生物及其制备方法和应用
CN110229168A (zh) * 2019-06-25 2019-09-13 郑州大学 11,20-二羰基济源冬凌草甲素及其l-氨基酸-14-酯三氟乙酸盐
CN114890971A (zh) * 2022-04-08 2022-08-12 中国科学院昆明植物研究所 毛萼内酯素b衍生物及其药物组合物与抗新冠肺炎的应用

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0769886A (ja) * 1993-09-03 1995-03-14 Lotte Co Ltd 抗う蝕、歯周病剤およびこれを含有する口腔用組成物
US20040048918A1 (en) * 2000-12-12 2004-03-11 Jung-Joon Lee Novel use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer
KR20030003215A (ko) * 2002-12-23 2003-01-09 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도
CN102002051A (zh) * 2010-10-18 2011-04-06 中国药科大学 具有抗肿瘤活性的ent-6,7-开环贝壳杉烯型冬凌草甲素衍生物、其制备方法及用途
CN102229598A (zh) * 2011-04-21 2011-11-02 新乡医学院 一种对映-贝壳杉型二萜类化合物及其制备方法和应用
CN103145726A (zh) * 2013-02-26 2013-06-12 中国科学院昆明植物研究所 一种对映-贝壳杉烷二萜化合物及其药物组合物和应用
CN103467474A (zh) * 2013-09-17 2013-12-25 中国药科大学 1,6,7,14-位取代的冬凌草甲素衍生物、制备方法及用途
WO2018059372A1 (en) * 2016-09-27 2018-04-05 Hong Kong Baptist University Method of use of diterpenoid derivatives as anticancer agents
CN108299458A (zh) * 2017-12-28 2018-07-20 青岛海洋生物医药研究院股份有限公司 冬凌草甲素衍生物及其制备方法和应用
CN110229168A (zh) * 2019-06-25 2019-09-13 郑州大学 11,20-二羰基济源冬凌草甲素及其l-氨基酸-14-酯三氟乙酸盐
CN114890971A (zh) * 2022-04-08 2022-08-12 中国科学院昆明植物研究所 毛萼内酯素b衍生物及其药物组合物与抗新冠肺炎的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
刘旭: "冬凌草中1个新的对映-贝壳杉烷二萜", 中草药, vol. 52, no. 23, pages 7083 - 7087 *
刘洪川: "冬凌草甲素的结构修饰研究进展", 药学实践杂志, vol. 34, no. 2, pages 114 - 115 *
戴一: "冬凌草甲素的结构修饰与生物活性研究进展", 有机化学, vol. 37, no. 7, pages 1701 - 1713 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114890971A (zh) * 2022-04-08 2022-08-12 中国科学院昆明植物研究所 毛萼内酯素b衍生物及其药物组合物与抗新冠肺炎的应用
CN114890971B (zh) * 2022-04-08 2023-09-15 中国科学院昆明植物研究所 毛萼内酯素b衍生物及其药物组合物与抗新冠肺炎的应用

Also Published As

Publication number Publication date
CN114805269B (zh) 2023-09-15

Similar Documents

Publication Publication Date Title
CN112979733B (zh) 抗乙肝病毒的化合物及其制备方法和应用
CN110627755A (zh) 一种γ-丁内酯二聚体抗癌化合物及其制备方法
CN114805269B (zh) 毛萼内酯素b衍生物与其在制备抗肿瘤药物中的应用
CN113735709A (zh) 一种大麻二酚-2-丁酸酯及其应用
CN113666824A (zh) 一种大麻二酚-2-丙酸酯及其应用
CN107849002B (zh) 一种线叶旋覆花内酯a衍生物
CN113336765B (zh) 一种莪术醇酯化物、制备方法及其在治疗结直肠癌药物中的应用
CN113173964A (zh) 一种抗肿瘤的白桦醇衍生物及其制备方法
CN114890866B (zh) β-榄香烯卤代物及其制备方法
CN113372320B (zh) 蝗虫内生真菌次级代谢产物及其提取方法和应用
CN110818728A (zh) 多硫代二酮哌嗪类化合物Secoemestrin C的制备方法及其用途
CN113480590B (zh) 雷公藤大戟酮(wilfordeuphone)及其制备方法和在药物上的应用
CN115073406B (zh) 一种桉烷型倍半萜内酯类tba衍生物及其用途
CN111777577A (zh) 一类紫杉醇衍生物及其在制备防治人恶性肿瘤药物中的用途
CN115057839A (zh) 一种桉烷型倍半萜烯内酯化合物及其制备和用途
CN113582878B (zh) 一种天然产物对映-贝壳杉烷型二萜sgp-17的衍生物sgp-17-52
CN110078770A (zh) 一种具有喹啉酮四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用
CN113880793B (zh) 一种丁内酯衍生物的合成方法及其在抗过敏药物中的应用
CN115417857B (zh) 一种中药八角枫中的哌啶类生物碱及其提取纯化、半合成方法和应用
CN109734768A (zh) 去乙酰西地兰葡萄糖基改性化合物脂质体及其应用
CN114805270A (zh) 毛萼内酯素a和毛萼内酯素b及其制备方法
CN103172555B (zh) 升麻中分离的吲哚生物碱化合物、制备方法及其用途
CN102633792A (zh) 一种制备埃博霉素d和b的方法
CN116178463B (zh) 一种蒽酮糖苷类化合物及其制备方法和应用
CN116854704B (zh) 具有抗肝癌活性的瑞香烷二萜衍生物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant